Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Crescent Biopharma (CBIO) Accumulated Depreciation & Amortization (2016 - 2023)

Crescent Biopharma (CBIO) has disclosed Accumulated Depreciation & Amortization for 9 consecutive years, with $2.5 million as the latest value for Q3 2023.

  • For Q3 2023, Accumulated Depreciation & Amortization rose 7.23% year-over-year to $2.5 million; the TTM value through Sep 2023 reached $2.5 million, up 7.23%, while the annual FY2022 figure was $2.4 million, 2.74% up from the prior year.
  • Accumulated Depreciation & Amortization hit $2.5 million in Q3 2023 for Crescent Biopharma, up from $2.5 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $2.5 million in Q3 2023 and bottomed at $1.9 million in Q1 2020.
  • Average Accumulated Depreciation & Amortization over 4 years is $2.3 million, with a median of $2.3 million recorded in 2022.
  • Year-over-year, Accumulated Depreciation & Amortization increased 12.03% in 2022 and then increased 2.03% in 2023.
  • Crescent Biopharma's Accumulated Depreciation & Amortization stood at $2.1 million in 2020, then rose by 8.94% to $2.3 million in 2021, then increased by 2.74% to $2.4 million in 2022, then increased by 5.18% to $2.5 million in 2023.
  • According to Business Quant data, Accumulated Depreciation & Amortization over the past three periods came in at $2.5 million, $2.5 million, and $2.4 million for Q3 2023, Q2 2023, and Q1 2023 respectively.